Close

ARIAD Pharma (ARIA) Shares Drop to Session Lows

Go back to ARIAD Pharma (ARIA) Shares Drop to Session Lows

JPMorgan Downgrades ARIAD Pharmaceuticals (ARIA) to Underweight

October 24, 2016 6:37 AM EDT

(Updated - October 24, 2016 10:00 AM EDT)

JPMorgan downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Neutral to Underweight with a price target of $7.00. Analyst Anupam Rama anticipates more volatility, as concerns about valuation are coupled with political headline risk related to Iclusig pricing.

"We do not expect to see resolution of these political / pricing headlines, nor clarity on the appropriate dose for Iclusig in the near term. As... More

ARIAD Pharma (ARIA) Acknowledges Receipt of Congressional Letter; Issues Commentary

October 20, 2016 4:22 PM EDT

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) acknowledged the receipt of a Congressional... More

ARIAD Pharma (ARIA) lower after Bernie Sanders sends letter on pricing

October 20, 2016 1:01 PM EDT

ARIAD Pharma (NASDAQ: ARIA) lower after Bernie Sanders sends letter on pricing

... More

ARIAD Pharma (ARIA) Receives Document Request from Sanders, Cummings

October 20, 2016 1:01 PM EDT

(Updated)

ARIAD Pharma (NASDAQ: ARIA) shares were pressured Thursday after Representative Eliijah Cummings and Senator Bernard Sanders sent a letter to the company's CEO requesting information related to price increases on Iclusig, its treatment for chronic myeloid leukemia.

... More